Author

Joana Torres

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Joana Torres  et al.

IBD PATIENTS SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE PORTUGUESE COHORT OF THE IBD PODCAST STUDY
IBD PATIENTS SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE PORTUGUESE COHORT OF THE IBD PODCAST STUDY

Joana Torres  et al.

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

Joana Torres  et al.

WHAT IS THE REAL IMPACT OF THE HLA-DQA1*05 POLYMORPHISM ON INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
WHAT IS THE REAL IMPACT OF THE HLA-DQA1*05 POLYMORPHISM ON INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?

Joana Torres  et al.

SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS

Joana Torres  et al.

MAINTENANCE THERAPY AFTER AN EPISODE OF STEROID-RESPONSIVE ACUTE SEVERE ULCERATIVE COLITIS: WHAT IS THE BEST STRATEGY?
MAINTENANCE THERAPY AFTER AN EPISODE OF STEROID-RESPONSIVE ACUTE SEVERE ULCERATIVE COLITIS: WHAT IS THE BEST STRATEGY?

Joana Torres  et al.

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Joana Torres  et al.

DISAGREEMENT BETWEEN ENDOSCOPIC AND TRANSMURAL HEALING IN CROHN’S DISEASE AND THE IMPACT OF DISEASE DURATION
DISAGREEMENT BETWEEN ENDOSCOPIC AND TRANSMURAL HEALING IN CROHN’S DISEASE AND THE IMPACT OF DISEASE DURATION

Joana Torres  et al.

EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?
EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?

Joana Torres  et al.

EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS
EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS

Joana Torres  et al.

MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS
MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS

Joana Torres  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Joana Torres  et al.

PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)
PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)

Joana Torres  et al.

Item 21 - 33 / 33
1
2